Immedica Pharma AB /
Aeglea BioTherapeutics, Inc.
Immedica Pharma AB completes pegzilarginase asset purchase from Aeglea BioTherapeutics, Inc.
What happened
Immedica Pharma AB purchased Aeglea BioTherapeutics, Inc.’s assets related to its pegzilarginase program. The transaction included $15,000,000 in cash at closing and up to $100,000,000 in milestone payments.
Aeglea BioTherapeutics is a biotechnology company advancing antibody therapeutics for inflammatory bowel disease.
The source
Everything on this page comes from the source below.
Immedica Pharma AB completes pegzilarginase asset purchase from Aeglea BioTherapeutics, Inc.
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly